NLS Pharmaceutics Retained Earnings vs. EBITDA
| NLSPW Stock | USD 0.01 0 18.18% |
Retained Earnings | First Reported 2010-12-31 | Previous Quarter -70.4 M | Current Value -66.9 M | Quarterly Volatility 19.8 M |
For NLS Pharmaceutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NLS Pharmaceutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NLS Pharmaceutics AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NLS Pharmaceutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NLS Pharmaceutics AG over time as well as its relative position and ranking within its peers.
NLS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (2.28) |
The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NLS Pharmaceutics EBITDA vs. Retained Earnings Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NLS Pharmaceutics's current stock value. Our valuation model uses many indicators to compare NLS Pharmaceutics value to that of its competitors to determine the firm's financial worth. NLS Pharmaceutics AG is regarded third in retained earnings category among its peers. It is regarded fifth in ebitda category among its peers . NLS Pharmaceutics reported Retained Earnings of (70.37 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value NLS Pharmaceutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NLS EBITDA vs. Retained Earnings
Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
NLS Pharmaceutics |
| = | (70.37 M) |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
NLS Pharmaceutics |
| = | (11.8 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
NLS EBITDA Comparison
NLS Pharmaceutics is currently under evaluation in ebitda category among its peers.
NLS Pharmaceutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NLS Pharmaceutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NLS Pharmaceutics will eventually generate negative long term returns. The profitability progress is the general direction of NLS Pharmaceutics' change in net profit over the period of time. It can combine multiple indicators of NLS Pharmaceutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -158.1 K | -150.2 K | |
| Net Interest Income | -145.2 K | -152.4 K | |
| Interest Income | 505.9 K | 681.3 K | |
| Operating Income | -11.8 M | -12.4 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Income Before Tax | -12.2 M | -12.8 M | |
| Total Other Income Expense Net | -365 K | -383.2 K | |
| Net Loss | -3.3 M | -3.5 M | |
| Net Loss | -12.2 M | -12.8 M | |
| Income Tax Expense | 1.80 | 1.71 | |
| Net Loss | (0.32) | (0.33) | |
| Income Quality | 0.80 | 0.52 |
NLS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NLS Pharmaceutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NLS Pharmaceutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NLS Pharmaceutics' important profitability drivers and their relationship over time.
Use NLS Pharmaceutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.NLS Pharmaceutics Pair Trading
NLS Pharmaceutics AG Pair Trading Analysis
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NLS Pharmaceutics position
In addition to having NLS Pharmaceutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Military Industrial Thematic Idea Now
Military Industrial
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.